APPLICATION OF TRADITIONAL CHINESE MEDICINE COMPOSITION TO PREPARATION OF MEDICINE FOR TREATING OR PREVENTING CORONAVIRUS INFECTION

Abstract

An application of a traditional Chinese medicine composition to preparation of a medicine for treating or preventing coronavirus infection. The composition is prepared from the following raw material medicines in parts by weight: 1-3 parts of honey-fried herba ephedrae, 1-10 parts of semen armeniacae amarum, 1-6 parts of radix platycodonis, 1-6 parts of radix peucedani, 1-6 parts of bulbus fritillariae thunbergii, 1-6 parts of radix stemonae, 1-3 parts of oroxylum indicum, 1-10 parts of radix glehniae and 1-3 parts of radix glycyrrhizae. The diluent of the traditional Chinese medicine composition can protect Vero cells infected with 2019-nCov virus.

Claims

1-9. (canceled)

10. Application of a traditional Chinese medicine composition to preparation of a medicine for treating or preventing coronavirus infection, wherein the Chinese medicine composition comprising: 1-3 parts of honey-fried herba ephedrae, 1-10 parts of semen armeniacae amarum, 1-6 parts of radix platycodonis, 1-6 parts of radix peucedani, 1-6 parts of bulbus fritillariae thunbergii, 1-6 parts of radix stemonae, 1-3 parts of oroxylum indicum, 1-10 parts of radix glehniae and 1-3 parts of radix glycyrrhizae.

11. The application according to claim 10, wherein the coronavirus infection comprises COVID-19 infection.

12. The application according to claim 10, wherein the traditional Chinese medicine composition comprises: 1-1.5 parts of honey-fried herba ephedrae, 2-4 parts of semen armeniacae amarum, 1-3 parts of radix platycodonis, 1-3 parts of radix peucedani, 1-3 parts of bulbus fritillariae thunbergii, 1-3 parts of radix stemonae, 1-1.5 parts of oroxylum indicum, 2-4 parts of radix glehniae and 1-1.5 parts of radix glycyrrhizae.

13. The application according to claim 10, wherein the traditional Chinese medicine composition comprises: 1 part of honey-fried herba ephedrae, 3.33 parts of semen armeniacae amarum, 2 parts of radix platycodonis, 2 parts of radix peucedani, 2 parts of bulbus fritillariae thunbergii, 2 parts of radix stemonae, 1 part of oroxylum indicum, 3.33 parts of radix glehniae and 1 part of radix glycyrrhizae.

14. The application according to claim 10, wherein the traditional Chinese medicine composition comprises: 100 g of honey-fried herba ephedrae, 333 g of semen armeniacae amarum, 200 g of radix platycodonis, 200 g of radix peucedani, 200 g of bulbus fritillariae thunbergii, 200 g of radix stemonae, 100 g of oroxylum indicum, 333 g of radix glehniae and 100 g of radix glycyrrhizae.

15. The application according to claim 10, wherein the medicine for treating or preventing coronavirus infection comprises an oral administration dosage form, an injection administration dosage form or an external administration dosage form.

16. The application according to claim 15, wherein the medicine for treating or preventing coronavirus infection comprises decoction, tablet, capsule, granule, pill, injection, condensed decoction, suspending agent, dispersing agent, syrup, suppository, gel, aerosol, patch and oral liquid.

17. The application according to claim 10, wherein a preparation method of the traditional Chinese medicine composition comprises the following steps: taking the honey-fried herba ephedrae, the radix peucedani, the bulbus fritillariae thunbergii and the radix stemonae, adding 50%-80% ethanol in an amount which is 4-8 times the weight of the honey-fried herba ephedrae, the radix peucedani, the bulbus fritillariae thunbergii and the radix stemonae, refluxing for 1-3 hours, filtering, concentrating the filtrate under reduced pressure to obtain a clear paste; heating and boiling the radix platycodonis, the radix glehniae, the oroxylum indicum and the radix glycyrrhizae with water, then adding the semen armeniacae amarum and boiling, filtering, and concentrating the filtrate under reduced pressure to obtain a clear paste; and combining, uniformly mixing and drying the two clear pastes.

18. The application according to claim 17, wherein the preparation method of the traditional Chinese medicine composition comprises the following steps: adding 70% ethanol, in an amount which is 6 times the weight of the herba ephedrae, the radix peucedani, the bulbus fritillariae thunbergii and the radix stemonae, into the herba ephedrae, the radix peucedani, the bulbus fritillariae thunbergii and the radix stemonae, refluxing for 2 hours, filtering, adding 70% ethanol, in an amount which is 4 times the weight of medicine residues, into the medicine residues, refluxing for 2 hours, filtering, combining the filtrates, concentrating by using a thin film under reduced pressure to a relative density of 1.07 to obtain an alcohol-extracted clear paste; adding water, in an amount which is 10 times the weight of the semen armeniacae amarum, the radix glehniae, the radix platycodonis, the radix glycyrrhizae and the oroxylum indicum, into the semen armeniacae amarum, the radix glehniae, the radix platycodonis, the radix glycyrrhizae and the oroxylum indicum, adding the semen armeniacae amarum after boiling, boiling for 1.5 hours, filtering, adding water, in an amount which is 8 times the weight of medicine residues, into the medicine residues, boiling for 1.5 hours, filtering, combining the filtrate, concentrating by using a thin film under reduced pressure to a relative density of 1.09 to obtain a water-extracted clear paste; and combining, uniformly mixing and drying the clear pastes.

Description

DETAILED DESCRIPTION OF EMBODIMENTS

[0018] The present application provides application of a traditional Chinese medicine composition. Those skilled in the art may learn from the contents of the specification to appropriately improve process parameters. It should be noted that all the similar substitutions and modifications are obvious to those skilled in the art and should be considered to be included in the present application. The method and application of the present application have been described by preferred embodiments, and relevant personnel obviously can modify or appropriately change and combine the method and application of the specification without departing from the content, spirit and scope of the present application to implement and apply the technology of the present application.

[0019] Unless otherwise specified, medicines, biomaterials or instruments used in the present application are all common commercial products and can be purchased in the market.

[0020] The present application will be further described below with reference to embodiments.

[0021] Embodiment 1 Preparation of traditional Chinese medicine compound granules

[0022] The raw materials include: 100 g of honey-fried herba ephedrae, 333 g of semen armeniacae amarum, 200 g of radix platycodonis, 200 g of radix peucedani, 200 g of bulbus fritillariae thunbergii, 200 g of radix stemonae, 100 g of oroxylum indicum, 333 g of radix glehniae and 100 g of radix glycyrrhizae.

[0023] 70% ethanol, in an amount which was 6 times the weight of medicinal materials (decoction pieces) (herba ephedrae, radix peucedani, bulbus fritillariae thunbergii and radix stemonae), was added in the medicinal materials (decoction pieces) herba ephedrae, radix peucedani, bulbus fritillariae thunbergii and radix stemonae, refluxing was performed for 2 hours, filtering was performed, 70% ethanol, in an amount which was 4 times the medicinal residues, refluxing was performed for 2 hours, filtering was performed, the filtrates were combined, the filtrates was thin film concentrated under reduced pressure to a relative density of 1.07 (60° C.) to obtain an alcohol-extracted clear paste, and the clear paste was placed for future use. Water, in an amount which was 10 times the weight of five medicines (decoction pieces), was added into the five medicines (decoction pieces) such as semen armeniacae amarum, radix glehniae, radix platycodonis, radix glycyrrhizae and oroxylum indicum, where the semen armeniacae amarum was added after boiling, boiling was performed for 1.5 hours, filtering was performed, water, in an amount which was 8 times the weight of medicinal residues, was added in the medicinal residues, boiling was performed for 1.5 hours, filtering was performed, the filtrates were combined, and the filtrates was thin film concentrated under reduced pressure until a relative density of 1.09 (60° C.) to obtain a water-extracted clear paste. The clear paste was combined, mixed uniformly and spray-dried to obtain dry powder. Dextrin (37%-41% of the theoretical granule yield) and aspartame (1% of the theoretical granule yield) were added into the dry powder and mixed uniformly, dry granulation was performed, and subpackaging was performed by using aluminum foils (4.0 g in each bag) to obtain 1000 g of XingBei Cough granules.

Pharmaceutical Effect Test Example

[0024] 1. Experimental materials

[0025] Test medicine: 4 g of medicine prepared in Embodiment 1 of the present application was added with 10 ml of cell maintaining liquid. That is the original concentration 1 (1.7664 g crude medicine/mL).

[0026] Vero cell: preserved in Cell Bank of Institute of Microbiological Epidemiology.

[0027] 2019-nCoV virus: having a titer of 10.sup.7 TCID.sub.50/ml, and preserved in Virus Reservoir of Institute of Microbiological Epidemiology and P3 virus seed refrigerator at −80° C. The virus titer was 100TCID.sub.50.

[0028] 2. Experimental method

[0029] 100 μl of Vero cells with the concentration of 1×10.sup.5cell/ml was added into each well of a sterile 96-well culture plate, and cultivation was performed under the conditions of 37° C. and 5% CO.sub.2 for 24 hours; the test medicine was diluted into 6 concentrations (1:1, 1:10, 1:100, 1:1000, 1:10000, 1:100000), 4 duplicate-wells were set for each concentration, 100 μl of the test medicine was added in each well, action was performed for 1 hour, then isovolumetric 100 TCID50 viruses were added into each well and action was performed for 1 hour; after 1 hour, all cell culture fluid in the 96-well culture plate was discarded, and the diluted medicine liquid was added; meanwhile, cell control, blank control (solvent control) and virus control (negative control) were set; cells were incubated in an incubator under the conditions of 37° C. and 5% CO.sub.2 for 3 days; cytopathic effect (CPE) was observed under an optical microscope, complete cytopathic effect was recorded as “++++”, 75% cytopathic effect was recorded as “+++”, 50% cytopathic effect was recorded as “++”, 25% cytopathic effect was recorded as “+”, and non-cytopathic effect was recorded as “-”.

[0030] 3. Experiment condition: all the experimental operations were completed in BSL-3 laboratory.

[0031] 4. Result judgment: the cell without CPE has the effective concentration for inhibiting virus, and the cell with CPE has the non-effective concentration.

[0032] 5. Experimental results:

[0033] According to the present application, the medicine group has 6 concentrations, cytotoxicity is present at high concentrations (1:1 and 1:10), 2019-nCoV replication can be effectively inhibited at the concentrations of 1:100, 1:1000 and 1:10000, and there is no CPE activity caused by virus inhibition at low concentration (1:100000). The results are shown in Table 1.

TABLE-US-00001 TABLE 1 Anti-2019-nCoV Effect of Medicine Name of Test Medicine Concentration Result Medicines of the 1:1    / present application 1:10   / 1:100   − 1:1000  + 1:10000  ++ 1:100000 ++++ Virus control ++++ Cell control − / Cytotoxicity, “−” means no cytopathic effect; and “++++” means complete cytopathic effect.

[0034] 6. Conclusion:

[0035] According to the screening results of cell level, the samples prepared according to Embodiment 1 of the present application can inhibit CPE effect caused by virus at the concentrations of 1:100, 1:1000 and 1:10000, where the sample at the concentration of 1:100 has the strongest effect of inhibiting the CPE effect caused by virus. There is cytotoxicity at high concentrations (1:1 and 1:10), and there is no visible CPE activity caused by virus at low concentration (1:100000), indicating that the medicine provided by the present application has good anti-2019-nCoV activity in vitro.

[0036] It should be noted that those skilled in the art may learn from the contents of the specification to appropriately improve process parameters, and all the similar substitutions and modifications are obvious to those skilled in the art and should be considered to be included in the present application.